Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-associated Cancers

On August 17, 2020 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, reported that the first patient has been dosed with Precigen’s PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse platform designed to activate the immune system to recognize and target HPV+ solid tumors (clinical trial identifier: NCT04432597) (Press release, Precigen, AUG 17, 2020, View Source [SID1234563712]). HPV-associated cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase I portion of the study will use 3+3 dose escalation to evaluate the safety of PRGN-2009 administered as a monotherapy and to determine the recommended Phase II dose (R2PD) followed by an evaluation of the safety of the combination of PRGN-2009 at the R2PD and bintrafusp alfa (M7824), an investigational bifunctional fusion protein, in patients with recurrent or metastatic HPV-associated cancers. The Phase II portion of the study will evaluate PRGN-2009 as a monotherapy or in combination with bintrafusp alfa as a neoadjuvant or induction therapy in patients with newly-diagnosed stage II/III HPV16-positive oropharyngeal cancer.

PRGN-2009 leverages Precigen’s proprietary UltraVector and AdenoVerse platforms to optimize HPV antigen design. Such design is differentiated from other therapies due to the gorilla adenovector’s large payload capacity and potential for repeat administration due to very low to no seroprevalence in the human population.

PRGN-2009 is under development through a Cooperative Research and Development Agreement, or CRADA, with the laboratory of Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology (LTIB), Center for Cancer Research (CCR), National Cancer Institute (NCI). This CRADA has allowed Precigen to rapidly and cost-effectively advance PRGN-2009. The Phase I/II clinical trial of PRGN-2009 is being conducted at the NIH Clinical Center and will be led by Dr. Julius Strauss, Co-Director of the LTIB’s Clinical Trials Group, and Dr. James Gulley, Chief of the Genitourinary Malignancies Branch, CCR, NCI. For patients interested in enrolling in this clinical study, please call NCI’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email [email protected], and/or visit the website: View Source

"We appreciate working in collaboration with such renowned partners at the NCI to achieve this important milestone in our efforts to develop a new off-the-shelf immunotherapy treatment option for patients with HPV-associated cancers," said Helen Sabzevari, PhD, President and CEO of Precigen. "We are excited to investigate Precigen’s proprietary gorilla adenovector platform for the first time in a clinical setting and achieve this milestone during the COVID-19 global pandemic."

About HPV-associated Cancers
HPV infects the squamous cells that line the inner surfaces of certain organs and, consequently, most HPV-related cancers are a type of cancer called squamous cell carcinoma. Some cervical cancers come from HPV infection of gland cells in the cervix and are referred to as adenocarcinomas.1 HPV-related cancers include cervical, oropharyngeal, anal, penile, vaginal, and vulvar.1 Nearly 44,000 HPV-associated cancers occur in the United States each year. Of these, approximately 25,000 occur in women and 19,000 occur in men.2 HPV is considered responsible for more than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and more than 60% of penile cancers.2 Recent studies indicate that about 70% of cancers of the oropharynx also may be related to HPV.2

Precigen: Advancing Medicine with Precision
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.

References
1 HPV and Cancer, National Institutes of Health. Accessed in July 2020
2 HPV-Associated Cancer Statistics, Centers for Disease Control and Prevention. Accessed in July 2020

Trademarks
Precigen, AdenoVerse, UltraVector, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company’s business, including the timing and progress of preclinical and clinical trials and discovery programs, the promise of the Company’s portfolio of therapies, the Company’s refocus to a healthcare-oriented business, and its continuing evaluation of options for the Company’s non-healthcare businesses. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company’s clinical trial might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

WuXi Biologics Records Excellent Interim Results

On August 17, 2020 WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group," stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, reported its unaudited interim results for the six months ended June 30, 2020 (Press release, WuXi Biologics, AUG 17, 2020, View Source [SID1234563729]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2020 Interim Financial Highlights

Revenue: Achieved strong revenue growth of 21.0% year-on-year to RMB1,944.1 million despite the adverse impact of COVID-19, which caused two months of low productivity and a loss of revenue due to the delay of the regulatory inspection and global clinical trials. During this difficult time, the Group not only fulfilled previous commitments to our customers without missing any key project milestones, but also actively engaged in developing potential treatments for COVID-19, adding more than 10 COVID-19 projects within three months. This fully demonstrates how the Group’s leading technology platforms, competitive development timeline, and excellent track record have contributed to increased market share.
Gross profit and gross profit margin: Despite the ramp-up of three new manufacturing facilities and the adverse impact of COVID-19, gross profit increased by 17.3% year-on-year to RMB787.3 million, achieving an excellent gross profit margin of 40.5%. The strong growth of gross profit was attributable to the Group’s robust increase in the number of integrated projects, improved capacity utilization, operational efficiency and cost optimization at our existing sites, and the favourable impact from the appreciation of USD against RMB, partially offset by the increase of share-based compensation (SBC) costs.
Net profit, profit attributable to owners of the Company and net profit margin: Net profit grew by 62.6% year-on-year to RMB730.7 million, with net profit margin up by 960 basis points to 37.6%. By excluding the minority interest of the loss from its non-wholly owned subsidiaries, profit attributable to owners of the Company grew by 63.6% year-on-year to RMB736.1 million. Besides the robust results achieved in revenue and gross profit mentioned above, the following components also contributed to the significant growth of net profit: gains from investments and foreign exchange fluctuations; income tax refunds; other non-operating income recorded.
Adjusted net profit increased by 40.7% year-on-year to RMB734.0 million, with adjusted net profit margin up 540 basis points to 37.8%.
Diluted Earnings Per Share (EPS) increased by 55.9% from RMB0.34 to RMB0.53.
Adjusted diluted EPS increased by 38.5% from RMB0.39 to RMB0.54.
2020 Interim Operational Highlights

Despite experiencing the COVID-19 pandemic during the reporting period and facing significant business development challenges, the Group continued to gain more market share and recorded remarkable growth in the number of integrated projects. From June 30, 2019 to June 30, 2020, the number of projects increased from 224 to 286, in which late-phase (phase III) projects increased from 15 to 19.
Total backlog grew significantly from US$5,102 million as of December 31, 2019 to US$9,464.0 million as of June 30, 2020, with service backlog surging from US$1,686.0 million as of December 31, 2019 to US$5,773.0 million as of June 30, 2020. This was mainly driven by the signing of a long-term vaccine manufacturing contract and the addition of COVID-19 projects.
Four projects were transferred from global competitors, demonstrating that the value of the Group’s integrated enabling platform has been recognized by customers. Two of four projects are late-phase projects which will further establish a solid foundation for future commercial manufacturing. In addition, the Group signed the first commercial manufacturing project at the recently acquired Drug Product (DP) facility in Germany.
Amidst the pandemic, the Group received an increased number of inquiries for both regular discovery, development and manufacturing service in addition to the global COVID-19 neutralization antibody programs. The Group secured more than 10 COVID-19 projects within only three months, thus providing revenue upsides for the second half of this year and throughout 2021. The Group also successfully enabled three COVID-19 antibody IND filings during the reporting period and we will assist customers in bringing even more COVID-19 therapeutics into the clinic throughout the second half of this year.
The Group further shortened the standard IND project timeline from 15 months to 12 months, and as short as 2.5 months for a COVID-19 project. Providing these expedited project development timelines benefit patients around the world and offer another demonstration of how our extensive capacity and capabilities enable our clients and partners to bring novel biologics to the clinic and beyond.
The WuXiBody bispecific platform and the Group’s antibody-drug conjugates (ADC) platform were utilized by our customers and contributed to the Group’s growth. As of June 30, 2020, the WuXiBody platform has been used in 26 projects, and there are 30 ADC projects in development. These technology platforms will facilitate the Group’s expansion into more strategic collaborations with customers and better implement our "Follow-the-Molecule" strategy.
WuXi Vaccines, the Group’s subsidiary that serves as a vaccine contract development and manufacturing organization (CDMO), signed an approximately US$3 billion long-term manufacturing contract with a global vaccine leader and commenced the construction of a dedicated vaccine facility in Ireland. Vaccine CDMO is one of the next growth areas for the Group and will contribute substantially with expanded opportunities in the future.
The Group’s facility in Suzhou has received the European Medicines Agency (EMA) Good Manufacturing Practices (GMP) certificate, making the Group one of the few third-party biosafety testing providers certified by the EMA in China and the Asia-Pacific region.
As a global company, the Group continued to implement its "Global Dual Sourcing within WuXi Bio" strategy through various investments around the world. During the reporting period, the Group announced two biopharmaceutical clinical and manufacturing facilities in the U.S. and completed the acquisition of a biologics drug product (DP) manufacturing facility in Germany. These efforts helped the Group more effectively expand its global footprint and enable partners to develop and manufacture biologics via our industry leading supply chain.
The Group completed the weather-tight seal of its biologics drug substance (DS) manufacturing facility in Ireland only 10 months after initiating the facility’s construction. This timeline is another testament of our ability to construct facilities at "WuXi Bio Speed".
Despite the uncertainties of the COVID-19 pandemic, the Group’s business remained strong but it did not hinder our ability to retain and increase our talent base. As of June 30, 2020, the Group’s total number of employees reached 5,694, with over 2,400 scientists.
The Group will be included into the Hang Seng Index (HSI) in September 2020 only three years after its listing. This remarkable achievement makes the Group one of only three healthcare companies among HSI 50 constituents.
Employees’ safety and wellbeing are top priorities for the Group. During the initial outbreak of COVID-19 in China, the Group activated the Business Continuity Plan (BCP) and offered comprehensive solutions to ensure smooth business operations and to progress projects without missing milestones. As a result, a total of 38 new integrated projects have been added to the pipeline, including more than 10 COVID-19 related projects, which allowed the group to gain more market share. The Group’s advanced innovative technology platforms continued to play a significant role in enabling more partners, contributing more milestone payments and introducing more projects into the "Follow-the-Molecule" strategy.

Continues to Strengthen Technology Platforms to Better Enable Partners around the World

As an enabling platform, WuXi Biologics continues to improve its multiple technology platforms to expedite biologics discovery, development and manufacturing and enable our partners worldwide. The Group’s various technology platforms reinforce our industry-leading position, help increase market share and drive sustainable future growth.

The Group’s WuXiBodyTM bispecific antibody platform and ADC platform have quickly gained global market acceptance since their debut. As of June 30, 2020, the Group has secured 30 ADC projects and 26 WuXiBodyTM projects globally, reflecting customers’ recognition of the Group’s innovative technologies. Among the 30 ADC projects in the pipeline, 14 have reached IND stage, which will be the next wave of the global biologics innovation.

As one of the most efficient and high quality development platforms in the industry, the Group continued to challenge the business norm and further reduced the standard IND project timeline from 15 months to 12 months, and broke the industry record again with a 2.5-month timeline for a COVID-19 IND project. These competitive timelines validate our best-in-class technology platform and our ability to execute at a high level, which solidifies our industry-leading position.

WuXi Vaccines Begins to Unveil its Potential, Another High-growth Engine

Focusing on vaccine CDMO, WuXi Vaccines, a subsidiary of the Group, established a strategic partnership with a global vaccine leader by signing a 20-year vaccine production and supply contract at a total consideration of approximately US$3 billion. A WuXi Vaccines facility is under construction in Ireland to manufacture vaccines for the global market.

This strategic partnership has a historical significance for WuXi Biologics as it kicks off a new cooperation model for the global vaccine industry. This also marked the first important milestone just a year after the Group entered the vaccine business. The vaccine CDMO subsidiary is expected to witness enormous development opportunities and will thus continue to drive sustainable high growth for the Group.

Accelerates Global Footprints via Facility Expansion in the U.S. and Europe

As a global company, the Group continued to accelerate its global development by expanding its presence in the U.S. and Europe. The global capacity expansion allowed the Group to quickly respond to customers’ demands and cope with the market demands raised by unexpected challenges, such as COVID-19. The Group acquired a manufacturing facility in Germany and also expanded labs, clinical and manufacturing facilities in U.S., allowing it to better implement its "Global Dual Sourcing within WuXi Bio", namely to offer quality services to global customers and serve patients through a robust supply chain.

Construction of the main building of the Group’s biologics manufacturing site in Ireland was completed within ten months of its commencement. This manufacturing facility will house a 6,000L perfusion bioreactor (MFG6) thus pioneering the adoption of "next generation biologics production technology" (continuous manufacturing). In addition, the site will house 48,000L fed-batch cell culture bioreactor capacity (MFG7). Both MFG6 and MFG7 will implement the Group’s "scale-out" manufacturing paradigm by using single-use bioreactors for large-scale commercial manufacturing.

WuXi Biologics completed the acquisition of Bayer’s final drug product manufacturing facility in Leverkusen, Germany. This is also the Group’s second manufacturing facility in Europe.

As part of further expansion in the U.S. market, WuXi Biologics purchased a parcel of land to build a new commercial manufacturing facility in Worcester, Massachusetts, leased a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania, and signed a 10-year lease for a clinical manufacturing facility in Cranbury, New Jersey. These sites will facilitate the Group’s positioning to build an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry that can enable partners and benefit patients worldwide.

Actively Embraces Change and Turns Challenges into Opportunities

Faced with the COVID-19 pandemic, the Group promptly responded and leveraged its well-established BCP to bring business back to normal. The Group focused on keeping its employees safe and supporting our global customers’ work from home, while ensuring that projects progressed. The Group received high satisfaction from customers and this in turn improved even further customer retention. In addition, the Group made great contributions to the treatment and prevention of COVID-19 globally and witnessed rising demand for its outsourcing services due to the Group’s demonstrated timely response and extensive capacity and capabilities. The Group mobilized a dedicated R&D and manufacturing team with over 1,000 people and initiated projects on Chinese New Year’s Eve to enable the development of potential treatments for COVID-19.

Dr. Chris Chen, CEO of WuXi Biologics, said, "COVID-19 continues to challenge all of us in the global community, bringing great suffering to so many as well as an uncertain global economic outlook. WuXi Biologics also suffered from the pandemic that lead to two-month of low productivity and loss of revenue due to the delay of the regulatory inspection and global clinical trials. However, thanks to dedications from our employees and trust from our global customers, the Group delivered impressive performance which is beyond our expectations. Besides, the Group was selected as a constituent of HSI only three years after our listing, thus marking another great milestone for the Group. During the first half of 2020, WuXi Biologics delivered all key milestones for our global customers and took strong measures to enhance operational efficiency throughout the company. Our business relationships with our global customers significantly improved due to our strong project execution and performance during the worse period of the COVID-19 pandemic in China. Furthermore, we signed over 10 global COVID-19 neutralization mAb programs, allocated over 1,000 staff to work on these urgent programs and successfully enabled our partners to submit three COVID-19 antibody INDs within 3-5 months, at global record pace. As China recovered from the pandemic and due to an already booming innovative drug development trend in the domestic market, we have seen outstanding revenue growth in China. North America remains our most important market despite revenue growth slowdown due to the impact of the pandemic. The twelve newly added integrated projects from North America demonstrates that our business momentum from this market remains strong. Our industry-leading speed of execution and world-class quality has allowed us to win more customers from these established markets. Meanwhile, we have seen substantial growth from the rest of the world that also contributed to our overall business growth from these diversified markets. During this critical period, we leveraged our enabling platform to help our customers work from home and progress various projects to later stages. We broke another record by adding 38 integrated projects to our pipeline in the first six months of 2020. Our "Follow-the-molecule" strategy continues to be a proven driving force in maintaining our business momentum and in delivering sustainable high growth."

Dr. Chris Chen added, "By leveraging the Group’s world leading technology and excellent, highly-trained talent pool, the Group continues to shorten the R&D timeline and reduce manufacturing costs for customers. The disruptions caused by this pandemic have highlighted the need for extensive manufacturing capacities throughout the globe world and a robust global supply chain. Our strategy of establishing dual manufacturing sites worldwide in the past 3 years puts our customers in the most favourable situation during this unexpected crisis. Together, we can turn challenges into opportunities. Our capacity expansions in the U.S. and Europe will enable the Group to capture new opportunities, meet increasing demands from existing clients and attract potential business partners. Our integrated platform has been well accepted by our global customers who, by giving us new projects, demonstrates their faith in our ability to execute and deliver. This faith in our ability to deliver is witnessed as well by the increase in late-phase projects that went from 15 to 19 during this reporting period. The WuXiBody bispecific platform and ADC platform continue to play a significant role and drive additional growth. Furthermore, the contract signed by WuXi Vaccines and a global vaccine leader marks a huge leap in the vaccine CDMO business and delivers another driver of growth. With cutting-edge technology platforms, global capacity expansions, premier quality standards, experienced scientific teams and a proven track record, we are confident in achieving sustainable high growth in the foreseeable future."

Dr. Ge Li, Chairman of WuXi Biologics, concluded: "The COVID-19 pandemic has made this year challenging with unprecedented impact. The global communities are in urgent need of treatments to address the greatest health challenges posed by the pandemic. This is the reason we are investing approximately US$1 billion and continue to expand our capacities in U.S., Ireland and Germany to enable our global customers and partners for their drug discovery and development efforts and ultimately to benefit patients worldwide. We have made great strides over the past years and even throughout this difficult time to ultimately reach our vision of ‘Every drug can be made and every disease can be treated’."

2020 Interim Results

Revenue increased by 21.0% year-on-year to RMB1,944.1 million for the six months ended June 30, 2020. The major revenue growth drivers were: (i) immediate and effective implementation of Business Continuity Plan to minimize the impact of the COVID-19 pandemic on its business and operations; (ii) strong growth in development and manufacturing revenue resulting from improved utilization of existing sites; and (iii) more customer projects were added to the Group’s pipeline, expediting the development and manufacturing of potential treatments related to COVID-19 in support of its global customers.

Gross Profit increased by 17.3% to RMB787.3 million for the six months ended June 30, 2020. During the late second half of 2019, we commenced the production at three new sites, allowing the Group to gain new capabilities and capacities for biologics and antibody drug conjugates and a new state-of-the-art drug product fill facility. Despite the ramp-up of new facilities and the adverse impact from COVID-19, our gross profit continued to increase by 17.3% year-on-year to RMB787.3 million, achieving an excellent gross profit margin of 40.5%. The strong growth in gross profit was attributable to: (i) the Group’s robust increase in the number of integrated projects and improvement in capacity utilization, (ii) operational efficiency and cost optimization at our existing manufacturing facilities, (iii) favourable impact from the appreciation of USD against RMB, and (iv) partially offset by the ramp-up costs of newly commenced production sites and the increase of share-based compensation costs.

Operating Profit increased by 6.6% year-on-year to RMB411.1 million. The growth rate of operating profit was slightly slower than the growth of gross profit, mainly due to: (i) the increase of staff related costs and administrative expenses to support the set-up of new sites in the U.S. and Europe and the Group’s expansion into new business such as vaccines, antibody drug conjugates (ADC) production and microbial, (ii) to strengthen the Group’s corporate infrastructures such as IT infrastructure and enterprise solutions; and (iii) the Group’s continuous efforts to enhance the capability of the business development team.

Net Profit surged by 62.6% year-on-year to RMB730.7 million for the six months ended June 30, 2020, with net profit margin up 960 basis points to 37.6% for the first half of 2020. The significant increase in net profit margin was primarily attributable to (i) the Group’s robust increase in the number of integrated projects and, as a result, strong growth in revenue and gross profit; (ii) gains from investments and foreign exchange fluctuation; (iii) income tax refund; and (iv) partially offset by the increase of administrative expenses mentioned above and impairment provision recorded for doubtful accounts.

Adjusted Net Profit, by excluding the impact of (i) foreign exchange gain, and (ii) share-based compensation costs, increased by 40.7% year-on-year to RMB734.0 million for the first half of 2020. Adjusted net profit margin went up 540 basis points from 32.4% for the first half of 2019 to 37.8% of same period this year.

Basic and Diluted EPS were RMB0.57 and RMB0.53, increasing 54.1% and 55.9% year-on-year respectively.

Adjusted Diluted EPS increased by 38.5% year-on-year to RMB0.54.

Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020

On August 17, 2020 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that James F. Oliviero, President and Chief Executive Officer, will present a company overview and participate in a panel discussion at the Fortress Biotech Virtual Summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., on Wednesday, August 19, 2020 at 1:50 p.m. ET (Press release, Checkpoint Therapeutics, AUG 17, 2020, View Source [SID1234563713]). A registration link and webcast information can be found below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panel discussion will focus on cosibelimab, Checkpoint’s potentially best-in-class anti-PD-L1 antibody. Mr. Oliviero will be joined on the panel by David M. Miller, M.D., Ph.D., who will provide his insight on the use of immunotherapy in cutaneous squamous cell carcinoma ("cSCC") and the issues patients face when accessing available treatments. Dr. Miller is an Instructor in Dermatology and Medicine at Harvard Medical School and member of the Department of Dermatology and the Department of Medicine at Massachusetts General Hospital, where he is Director of the Center for Merkel Cell Carcinoma and Co-Director of the MGH-MEEI Non-Melanoma Skin Cancer Multi-Disciplinary Clinic.

Checkpoint will present updated interim safety and efficacy data from its ongoing registration-enabling clinical trial of cosibelimab in patients with metastatic cSCC at the European Society for Medical Oncology ("ESMO") Virtual Congress 2020, to be held September 19-21, 2020. Checkpoint recently announced that the trial is over half enrolled, with full enrollment anticipated around year-end.

Registration link and webcast information:

Please click here to register for the event on Wednesday, August 19, 2020.
Following the event, the webcast will be available on the Events page, located within the Investors section of Checkpoint’s website, View Source, for approximately 30 days.

China’s First Trastuzumab Biosimilar Approved by NMPA

On August 17, 2020 Shanghai Henlius Biotech, Inc. (2696.HK) reported on August 14 that the trastuzumab biosimilar HLX02, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA) (Press release, Shanghai Henlius Biotech, AUG 17, 2020, View Source [SID1234563730]). On 27th July, HLX02 (EU brand name Zercepac) has also been approved by the European Commission (EC), making HLX02 the first China-developed mAb biosimilar to be approved both in China and in the EU. The common name of HLX02 is trastuzumab injection (150mg/vial, without preservative) and it is indicated for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer. Trastuzumab has been included in China’s National Reimbursement Drug List (NRDL) in 2017. According to the "Interim Measures for the Administration of Drugs in the NRDL", drugs in the NRDL are managed by their common names, and drugs with common names that have been listed in the NRDL will automatically enter the NRDL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the development process of HLX02, Henlius strictly followed the NMPA and European Medicines Agency (EMA) biosimilar guidelines and has taken multiple head-to-head comparisons between HLX02 and the reference trastuzumab. Results from analytical studies, preclinical studies, a Phase 1 clinical study and a global multi-centre Phase 3 clinical study showed that HLX02 is highly similar to the reference trastuzumab in terms of quality, safety and efficacy. Henlius has implemented the concept of QbD (quality by design) in process development for HLX02 and has adopted single-use technology for its manufacturing, leading to decreased risk of contamination and increased production efficiency. Manufacturing site of HLX02 and its quality management system have passed multiple on-site inspections and audits by NMPA, EMA, EU Qualified Persons (QP) and international business partners of Henlius, and have obtained China and EU GMP certificates. To accelerate the commercialisation of HLX02, Henlius has built a professional and efficient international commercial team and established an innovative commercial model.

Dr. Scott Liu, co-founder and CEO of Henlius, said, "As the leading company in the biologics industry of China, Henlius’ self-developed rituximab biosimilar HLX01 was approved by the NMPA in 2019, making it the first biosimilar in China. Now we are proud that HLX02 can benefit Chinese patients. The recognition of HLX02 by domestic and international regulatory authorities is the results of insisting the quality standards of Henlius, and Henlius will continue making efforts in providing affordable and effective therapies for patients worldwide."

Mr. Wenjie Zhang, President of Henlius, said, "HLX02 is the second product successfully approved for launch of Henlius and the first product that has received recognition from international drug regulatory agency. We are very grateful to all the physicians, nurses, patients and regulatory authorities that have contributed to or supported the studies of HLX02. We hope that HLX02 will benefit HER2-positive breast cancer and gastric cancer patients both in urban and rural areas in China."

Mustang Bio to Present at the Virtual Fortress Biotech Corporate Access Summit

On August 17, 2020 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in the two-day Fortress Biotech ("Fortress") Virtual Summit taking place on Tuesday, August 18 and Wednesday, August 19 (Press release, Mustang Bio, AUG 17, 2020, View Source [SID1234563714]). The Summit will be hosted by the B. Riley FBR, Inc., Research team and feature multiple programs from Fortress’ diversified pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Tuesday, August 18, Dr. Litchman will present Mustang’s gene therapy programs and participate in a panel with Harry L. Malech, M.D., Chief of the Genetic Immunotherapy Section for the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The panel will take place at 2:50 p.m. ET and registration for the event is available here.

Dr. Litchman will also present Mustang’s cancer cell therapy programs and participate in a panel with Stephen J. Forman, M.D., Professor in the Department of Hematology & Hematopoietic Cell Transplantation and Director of City of Hope’s T Cell Therapeutics Research Laboratory on Wednesday, August 19, 2020. The panel will take place at 1:20 p.m. ET and registration for the event is available here.
Following each event, the webcasts will be available on the Events page, located within the Investor Relations section of Mustang’s website, View Source, for approximately 30 days.